Literature DB >> 17204369

Phenotypic associations of tau and ApoE in Parkinson's disease.

Spiridon Papapetropoulos1, Matthew J Farrer, Jeremy T Stone, Nicole M Milkovic, Owen A Ross, Linda Calvo, Donald McQuorquodale, Deborah C Mash.   

Abstract

Overlaps in clinical, pathological and molecular features of Parkinson's disease (PD), dementing and motor tauopathies have prompted association studies in search of common genetic risk factors that may predispose or modify this spectrum of disorders. To explore possible phenotypic implications, we studied common tau and ApoE gene polymorphisms, associated with Alzheimer's disease (AD), progressive supranuclear palsy (PSP) and PD, in a clinically and pathologically characterized cohort of PD patients and aged control subjects. Our results reveal a novel association between PD-related hallucinations and H1H1 genotype. We also report an association between PDD and the presence of the ApoE epsilon4 allele. Better determination of subsets of PD patients based upon the presence of specific phenotypic features may improve the accuracy of association studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17204369     DOI: 10.1016/j.neulet.2006.12.008

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  21 in total

1.  APOE and CYP2E1 polymorphisms, alcohol consumption, and Parkinson's disease in a Japanese population.

Authors:  Chikako Kiyohara; Yoshihiro Miyake; Midori Koyanagi; Takahiro Fujimoto; Senji Shirasawa; Keiko Tanaka; Wakaba Fukushima; Satoshi Sasaki; Yoshio Tsuboi; Tatsuo Yamada; Tomoko Oeda; Takami Miki; Nobutoshi Kawamura; Nobutaka Sakae; Hidenao Fukuyama; Yoshio Hirota; Masaki Nagai
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

Review 2.  Apolipoprotein E in Alzheimer's disease and other neurological disorders.

Authors:  Philip B Verghese; Joseph M Castellano; David M Holtzman
Journal:  Lancet Neurol       Date:  2011-03       Impact factor: 44.182

3.  Genetic influences on cognitive decline in Parkinson's disease.

Authors:  James F Morley; Sharon X Xie; Howard I Hurtig; Matthew B Stern; Amy Colcher; Stacy Horn; Nabila Dahodwala; John E Duda; Daniel Weintraub; Alice S Chen-Plotkin; Vivianna Van Deerlin; Dana Falcone; Andrew Siderowf
Journal:  Mov Disord       Date:  2012-02-16       Impact factor: 10.338

4.  Apolipoprotein E genotypes and the risk of Parkinson disease.

Authors:  Jianjun Gao; Xuemei Huang; Yikyung Park; Rui Liu; Albert Hollenbeck; Arthur Schatzkin; Richard B Mailman; Honglei Chen
Journal:  Neurobiol Aging       Date:  2011-07-08       Impact factor: 4.673

5.  Brain amyloid and cognition in Lewy body diseases.

Authors:  Stephen N Gomperts; Joseph J Locascio; Marta Marquie; Andrea L Santarlasci; Dorene M Rentz; Jacqueline Maye; Keith A Johnson; John H Growdon
Journal:  Mov Disord       Date:  2012-06-12       Impact factor: 10.338

Review 6.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

7.  Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection.

Authors:  Shiek Ssj Ahmed; Winkins Santosh; Suresh Kumar; Hema T Thanka Christlet
Journal:  J Biomed Sci       Date:  2009-07-13       Impact factor: 8.410

8.  Apolipoprotein E polymorphisms and primary glaucoma in Saudis.

Authors:  Najwa Mohammed Al-Dabbagh; Nourah Al-Dohayan; Misbahul Arfin; Mohammad Tariq
Journal:  Mol Vis       Date:  2009-05-04       Impact factor: 2.367

9.  Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease.

Authors:  Caroline H Williams-Gray; An Goris; Misuzu Saiki; Thomas Foltynie; D Alastair S Compston; Stephen J Sawcer; Roger A Barker
Journal:  J Neurol       Date:  2009-03-18       Impact factor: 4.849

Review 10.  The psychosis spectrum in Parkinson disease.

Authors:  Dominic H Ffytche; Byron Creese; Marios Politis; K Ray Chaudhuri; Daniel Weintraub; Clive Ballard; Dag Aarsland
Journal:  Nat Rev Neurol       Date:  2017-01-20       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.